Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in Recurrent Glioblastoma
NCT00250887Phase 2Completed
- Sponsor
- University of Zurich
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in glioblastoma (GBM), sponsored by University of Zurich. Primary endpoint: molecular signature of EGFR responsiveness to ZD1839. Started Jul 2005; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00250887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250887.